Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Arch Tradit Pharmacol 4(2):8388
*Based on published clinical studies of FDA-approved branded GLP-1 medications
The 2023 phase 2 double-blind, randomized controlled trial evaluating a GLP-1/GIP/glucagon receptor triagonist (retatrutide) in patients with the disease of obesity reported 24.2% weight loss at 48 weeks with 12 mg retatrutide
SAGE Journals+1 Safety (preclinical): multi-species toxicology work (mice, rats, rabbits, dogs) reported good tolerability at tested doses
Telehealth services now allow patients to consult with providers and access semaglutide prescriptions from home
US$ 24.95
US$ 21.44
US$ 29.42
US$ 20.40
US$ 24.09
US$ 29.57
US$ 23.80
